



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) Publication number:

0 442 378 A1

(12)

EUROPEAN PATENT APPLICATION

(21) Application number: 91101663.2

(51) Int. Cl.⁵: C07F 9/572

(22) Date of filing: 07.02.91

(30) Priority: 16.02.90 US 481009

(43) Date of publication of application:
21.08.91 Bulletin 91/34

(84) Designated Contracting States:
AT BE CH DE DK ES FR GB GR IT LI LU NL SE

(71) Applicant: E.R. SQUIBB & SONS, INC.
P.O.Box 4000
Princeton New Jersey 08543-4000(US)


(72) Inventor: Grosso, John A.
7 Penbrook Court
Princeton Junction, NJ 08550(US)

(74) Representative: Josif, Albert et al
Baaderstrasse 3
W-8000 München 5(DE)

(54) Selective processes for fosinopril polymorphs.

(57) Described herein is a process for selectively preparing and interconverting polymorph salts of fosinopril, an antihypertensive agent that inhibits angiotensin converting enzyme. Each polymorph is prepared by mixing an alkali metal carrier, fosinopril, water and a keto and/or hydroxylic solvent and isolating the polymorph formed from the reaction mixture. The less exothermic polymorph A is formed when the water makes up more than about 0.2% of the water and solvents; at about 0.2% or less, the more exothermic polymorph B is formed.

FIG. 1



EP 0 442 378 A1

EP 0 442 378 A1

This invention relates to processes for the preparation and interconversion of polymorphs of fosinopril, an inhibitor of angiotensin converting enzyme (ACE) useful as an antihypertensive agent.


U.S. Patent No. 4,337,201 (issued June 29, 1982) describes inter alia the compound

5

10

15

20



25

which has the generic name fosinopril and forms the alkali metal salt $[1[S^*(R^*)],2\alpha,4\beta]-4\text{-cyclohexyl-1-}[[[2\text{-methyl-1-(1-oxopropoxy)propoxy}](4\text{-phenylbutyl)phosphinyl}]acetyl]\text{-L-proline}$, monosodium salt. Fosinopril and related compounds are ACE inhibitors having antihypertensive activity and other utilities as described in U.S. Patent No. 4,337,201.

30

Calorimetric, spectroscopic, and other analyses have established that fosinopril sodium exists as two polymorphs, A and B (see Figures 1 to 4). Figure 1 shows a differential scanning calorimetry thermogram of the two polymorphs. Figure 2 shows powder X-ray diffraction spectra of the two polymorphs. Figures 3A and 3B show infrared diffuse reflectance spectra of the polymorphs. Figure 4 shows carbon-13 NMR spectra of the two polymorphs. Polymorph B has been found to be much more exothermic than polymorph A upon dissolving, so that polymorph A is believed to be more thermodynamically stable (see Table 1, below).

35

TABLE 1

40

Heats of Solution of Two Different Polymorphs of Fosinopril Sodium

45

Form A: $\Delta H_S = -0.90 \text{ Kcal/mole}$

Form B: $\Delta H_S = -2.46 \text{ Kcal/mole}$

When fosinopril salt or fosinopril and an alkali metal carrier are placed in a keto or hydroxylic solvent or mixture thereof, the amount of water present determines which polymorph is formed. When the water comprises greater than about 0.2% of the amount of water and solvents added together, formation of polymorph A predominates. No water need be present for formation of polymorph B. When the water comprises about 0.2% or less of the amount of water and solvents added together, formation of polymorph B predominates. In either case, the polymorph formed crystallizes and is conventionally isolated from the solution.

In accordance with the present invention, a process is provided for preparing fosinopril-alkali metal salt polymorph A from either fosinopril (structure I) or polymorph B. In this process, either polymorph B or fosinopril and an alkali metal carrier are mixed with water and a keto or hydroxylic solvent or mixture thereof, after which polymorph A is isolated from the mixture. Water should be present in an amount greater than about 0.2% of the total amount of water and solvents added together. It is preferred that the amount of

water present be limited, however, to minimize the amount of product lost to the mother liquor. Thus, it is preferred that the water comprise about 1 to 3% of the amount of water and solvents together.

Also in accordance with the present invention, a process is provided for preparing fosinopril-alkali metal salt polymorph B from fosinopril or polymorph A. In this process, polymorph A or fosinopril and an alkali metal carrier are mixed with a keto or hydroxylic solvent or mixture thereof having about 0.2 to 0% water (i.e., no water present), after which polymorph B is isolated from the mixture.

Further in accordance with the present invention, a process is provided for preparing polymorph B in which water is removed from a solution of (1) polymorph A or (2) fosinopril and an alkali metal carried in a keto or hydroxylic solvent or mixture thereof and polymorph B is isolated from the solution. Removal of the water should be effected so that the amount of water is less than about 0.2% of the amount of the water and solvents together. Removal by vacuum concentration is preferred.

Throughout this specification, the term "alkali metal" refers to sodium (which is preferred), lithium, and potassium. Exemplary alkali metal carriers are sodium ethylhexanoate (which is preferred), potassium ethylhexanoate, lithium ethylhexanoate, and the like.

Exemplary keto solvents are acetone (which is preferred), methylethylketone, methylisobutylketone, and the like. Exemplary hydroxylic solvents are methanol (which is preferred), ethanol, isopropyl alcohol, and the like. Other solvents may be present but are not required.

The mixing step of the processes of the present invention may be accomplished by, for example, slurring or stirring. Isolation may be accomplished by, for example, filtration of the reaction mixture.

The invention will now be further described by the following working examples, which are preferred embodiments and are illustrative rather than limiting. All temperatures are in degrees Celsius.

Example 1

Preparation of Fosinopril Sodium Polymorph A

A solution of 20.0 g of the cinchonidine salt, [R-(R*,S*)]-[[2-methyl-1-(1-oxopropoxy)-propoxy]-(4-phenyl-butyl)phosphinyl]acetic acid, cinchonidine salt (1:1) in 200 ml of methylene chloride was washed with three 200-ml portions of distilled water, each time adjusting the pH of the biphasic mixture to 2.0 with 6 N hydrochloric acid. Following the addition of 0.06 g of pyridine and 2.98 g of triethylamine, the solution was cooled to -10° C. To the cold solution was added 3.62 g pivaloyl chloride. The reaction mixture was stirred for 1 hour, followed by the addition of 6.88 g of (trans)-4-cyclohexyl-L-proline, monohydrochloride and 2.98 g of triethylamine. The mixture was then warmed to 25° C and stirred for 90 minutes at that temperature. The product-rich solution was washed with three 200-ml portions of water, each time adjusting the pH of the biphasic mixture to 2.0 with 6 N hydrochloric acid. The organic layer was concentrated under vacuum to 21 g of an amber oil.

The oil was dissolved in 200 ml of acetone and 30.0 ml of 1 N sodium ethylhexanoate in acetone containing 13.56 percent water by volume. After stirring the crystal slurry for 6 hours at room temperature, the product was collected by filtration and washed on the filter with 70 ml of acetone. The wet cake was dried under vacuum, yielding 15.2 g (87.8 M%) of fosinopril sodium polymorph A.

Example 2

Conversion of Polymorph B to Polymorph A

To a mixture of 490 ml of acetone and 10 ml of water was added 50.1 g of fosinopril sodium polymorph B. The slurry was stirred for 2 hours at room temperature and the product was isolated by filtration. Vacuum-drying afforded 49.5 g (99 M%) of fosinopril sodium polymorph A.

Example 3


Conversion of Polymorph A to Polymorph B

To 15 ml of methanol was added 1.0 g of fosinopril sodium polymorph A. The resultant solution was vacuum-concentrated at 35° C to dryness, yielding 1.0 g of fosinopril sodium polymorph B.

Claims

1. A process for selectively preparing a fosinopril salt polymorph, which comprises:
 - (a) mixing together
 - (i) either (1) fosinopril salt or (2) fosinopril and an alkali metal carrier,
 - (ii) a keto solvent or a hydroxylic solvent or a mixture thereof, and
 - (iii) water;
 - (b) regulating the amount of water present so that the water comprises more than 0.2% of the water and solvents to form polymorph A, or 0.2% or less to form polymorph B; and
 - (c) isolating the polymorph formed from the mixture.
2. The process of Claim 1, wherein the alkali metal is sodium.
3. The process of Claim 1, wherein a keto solvent is used to prepare polymorph A.
4. The process of Claim 3, wherein the keto solvent is acetone.
5. The process of Claim 1, wherein a hydroxylic solvent is used to prepared polymorph B.
6. The process of Claim 5, wherein the hydroxylic solvent is methanol.
7. The process of Claim 1, wherein the alkali metal carrier is sodium ethylhexanoate.
8. The process of Claim 1, wherein the amount of water is about 1 to 3% of the water and solvents so that polymorph A is formed.
9. The process of Claim 1, wherein the amount of water is regulated by removing water so that the water comprises about 0.2% or less of the water and solvents in the mixture and polymorph B is formed.
10. The process of Claim 9, wherein the water is removed by vacuum concentration.

FIG. 1






FIG. 3A




FIG. 3B





FIG. 4





European
Patent Office

EUROPEAN SEARCH REPORT

Application Number

EP 91 10 1663

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl.5)
D,A	US-A-4 337 201 (E.W. PETRILLO, Jr.) * Whole document * -----	1-10	C 07 F 9/572
			TECHNICAL FIELDS SEARCHED (Int. Cl.5)
			C 07 F 9/00
The present search report has been drawn up for all claims			
Place of search The Hague		Date of completion of search 05 April 91	Examiner BESLIER L.M.
<div><div>CATEGORY OF CITED DOCUMENTS X: particularly relevant if taken alone Y: particularly relevant if combined with another document of the same category A: technological background O: non-written disclosure P: intermediate document T: theory or principle underlying the invention</div><div>E: earlier patent document, but published on, or after the filing date D: document cited in the application L: document cited for other reasons ----- &: member of the same patent family, corresponding document</div></div>			